篇名 | Worse Prognosis in Heart Failure Patients with 30-Day Readmission |
---|---|
卷期 | 32:6 |
作者 | Ying-Chang Tung 、 Shing-Hsien Chou 、 Kuan-Liang Liu 、 I-Chang Hsieh 、 Lung-Sheng Wu 、 Chia-Pin Lin 、 Ming-Shien Wen 、 Pao-Hsien Chu |
頁次 | 698-707 |
關鍵字 | Heart failure 、 Prognosis 、 Readmission 、 MEDLINE 、 SCI 、 Scopus |
出刊日期 | 201611 |
DOI | 10.6515/ACS20151113A |
Background: Heart failure (HF) readmission results in substantial expenditure on HF management. This study aimed to evaluate the readmission rate, outcome, and predictors of HF readmission.
Methods: Patients with reduced left ventricular ejection fraction (LVEF < 40%) who were admitted for acute decompensation of de novo HF were enrolled to analyze readmission rate, mortality and predictors of readmission.
Results: A total of 433 de novo HF patients with LVEF < 40% were enrolled during the period August 2013 to December 2014. The in-hospital and 6-monthmortality rates were 3.9% and 15.2%, respectively. In those patients surviving the index HF hospitalization, the 30-day and 6-month readmission rates were 10.9% and 27%, respectively. At the end of the 6-month follow-up, the readmission group had higher mortality than the non-readmission group (27.66% vs. 10.36%; p = 0.001). The survivors of the 30-day readmission had similar mortality rates at 6 months, regardless of the cause of readmission (cardiovascular vs. non-cardiovascular: 25% vs. 30.43%, p = 0.677). Among all the parameters, prescription of beta blockers independently reduced the risk of 30-day readmission (odds ratio 0.15; 95% confidence interval 0.02-0.99; p = 0.049).
Conclusions: Those HF patients who suffered from 30-day readmission had worse prognosis at the 6-month follow-up. Regardless of the readmission causes, the patients surviving the 30-day readmission had similar mortality rates at 6-month follow-up. These results underscored the importance of reducing readmission as a means to improve HF outcome.